UNSPSC 51162205: Camphor/eucalyptus oil/menthol

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE900. This VA Drug Class (RE900) classifies this compound as belonging to the group RESPIRATORY AGENTS, OTHER.

UNSPSC 51162205 Camphor/eucalyptus oil/menthol is a Commodity code covering specialized pharmaceutical and over-the-counter products including menthol-based remedies, topical analgesics, and inhalant products that state and local health systems, correctional facilities, and procurement cooperatives source through established pharmaceutical distribution networks. State and local buyers under this code operate primarily through multistate cooperative purchasing alliances and individual state health departments that consolidate demand across multiple facilities and jurisdictions to negotiate volume pricing and ensure consistent product availability through authorized pharmaceutical wholesalers.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products, including menthol-containing items, for distribution across participating state and local government facilities in Minnesota, Oregon, and other member jurisdictions. The solicitation requires vendors to supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—with all products available by May 15, 2026 and resulting agreements effective July 1, 2026. Evaluation weighting prioritizes price competitiveness (75 percent) alongside fixed pricing, administrative compliance, EDI capability, and agreement to a 3 percent administrative fee. Vendors must certify compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act, maintain relationships with at least two of the three authorized wholesalers with chargeback systems in place, and carry comprehensive insurance including commercial general liability of $5,000,000 per occurrence.